Corcept Therapeutics Incorporated (NASDAQ: CORT)
Hagens Berman Sobol Shapiro LLP reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the May 13, 2019 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Northern District of California.
If you purchased or otherwise acquired securities of CORT between August 2, 2017 and February 5, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing CORT@hbsslaw.com.
According to the complaint, during the class period Defendants misled investors by concealing (a) improper payments to doctors to promote its drug Korlym, (b) its aggressive promotion of Korlym for off-label uses, and (c) the possibility that the Company’s sole specialty pharmacy was a related party.
In response to reports highlighting this- and other- potential misconduct, the price of Corcept shares has significantly fallen.
“We’re focused on investors’ losses and whether Defendants used a captured pharmacy to improperly boost sales or hide losses,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.